These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 25363310

  • 21. Pharmaceuticals and medical devices: business practices. Issue brief.
    Steiner DJ.
    Issue Brief Health Policy Track Serv; 2012 Dec 31; ():1-36. PubMed ID: 23297448
    [No Abstract] [Full Text] [Related]

  • 22. [Generic medicines].
    Peláez de Loño J.
    Rev Enferm; 1999 Dec 31; 22(12):836-43. PubMed ID: 10797771
    [Abstract] [Full Text] [Related]

  • 23. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT.
    Mich Law Rev; 2015 Dec 31; 114(1):107-36. PubMed ID: 26394458
    [Abstract] [Full Text] [Related]

  • 24. Brazil and USA at loggerheads over production of generic antiretrovirals.
    Ahmad K.
    Lancet; 2001 Feb 10; 357(9254):453. PubMed ID: 11273079
    [No Abstract] [Full Text] [Related]

  • 25. Muddying the waters: how the Supreme Court's decision in Merck v. Integra fails to resolve problems of judicial interpretation of 35 U.S.C. Section 271(E)(1), the "safe harbor" provision of the Hatch-Waxman Act.
    Sertic M.
    Health Matrix Clevel; 2007 Feb 10; 17(2):377-439. PubMed ID: 18326397
    [No Abstract] [Full Text] [Related]

  • 26. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ, Thomson Reuters Accelus.
    Issue Brief Health Policy Track Serv; 2016 Dec 27; 2016():1-38. PubMed ID: 28252886
    [No Abstract] [Full Text] [Related]

  • 27. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M, Tempesta J, Ragusa P.
    Pharm Pat Anal; 2014 Jul 27; 3(4):345-7. PubMed ID: 25291307
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Indian biogenerics industry emerges.
    Jayaraman KS.
    Nat Biotechnol; 2003 Oct 27; 21(10):1115-6. PubMed ID: 14520378
    [No Abstract] [Full Text] [Related]

  • 31. Patent watch: US Supreme Court revises patent claim construction standards.
    Noonan K.
    Nat Rev Drug Discov; 2015 Mar 27; 14(3):157. PubMed ID: 25722233
    [No Abstract] [Full Text] [Related]

  • 32. Trade deal to curb generic-drug use.
    Maxmen A.
    Nature; 2012 Sep 06; 489(7414):16-7. PubMed ID: 22962700
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Should the patent system for new medicines be abolished?
    DiMasi JA, Grabowski HG.
    Clin Pharmacol Ther; 2007 Nov 06; 82(5):488-90. PubMed ID: 17952100
    [No Abstract] [Full Text] [Related]

  • 35. Patent watch.
    Harrison C.
    Nat Rev Drug Discov; 2013 Jan 06; 12(1):14-5. PubMed ID: 23274462
    [No Abstract] [Full Text] [Related]

  • 36. Lowering the cost of prescription drugs.
    Jindal B.
    J La State Med Soc; 2003 Jan 06; 155(1):51. PubMed ID: 12656276
    [No Abstract] [Full Text] [Related]

  • 37. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
    Engelberg AB.
    Spec Law Dig Health Care Law; 2000 Sep 06; (258):9-48. PubMed ID: 11184791
    [No Abstract] [Full Text] [Related]

  • 38. Novartis challenges India's drug patent laws in Supreme Court.
    Billingsley M.
    BMJ; 2012 Feb 21; 344():e1279. PubMed ID: 22354594
    [No Abstract] [Full Text] [Related]

  • 39. Patent infringement. Generic HIV drugmaker's patent claim is time-barred.
    AIDS Policy Law; 2003 Aug 29; 18(16):6. PubMed ID: 14626916
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.